These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32710097)

  • 1. Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube.
    McCreary EK; Nguyen MH; Davis MR; Borlagdan J; Shields RK; Anderson AD; Rivosecchi RM; Marini RV; Sacha LM; Silveira FP; Andes DR; Lepak AJ
    J Antimicrob Chemother; 2020 Oct; 75(10):3023-3028. PubMed ID: 32710097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enteral feeding tube administration with therapeutic drug monitoring of crushed posaconazole tablets and opened isavuconazonium sulfate capsules.
    Dieringer TD; Schaenman JM; Davis MR
    J Antimicrob Chemother; 2022 Apr; 77(5):1417-1423. PubMed ID: 35174391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic drug concentrations of isavuconazole following the administration of isavuconazonium sulfate capsules via gastro-jejunum tube: A case report.
    Adamsick ML; Elshaboury RH; Gift T; Mansour MK; Kotton CN; Gandhi RG
    Transpl Infect Dis; 2019 Apr; 21(2):e13048. PubMed ID: 30636363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Isavuconazole serum concentrations after enteral feeding tube administration in a hospitalized cohort: A case series.
    Spivey J; Wrenn R; Liu B; Maziarz E; Kram B
    J Clin Pharm Ther; 2021 Apr; 46(2):528-531. PubMed ID: 33247433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Pharmacokinetic Bioequivalence Study Comparing Different-Strength and -Size Capsules of Isavuconazonium Sulfate in Healthy Japanese Subjects.
    Shirae S; Mori Y; Kozaki T; Ose A; Hasegawa S
    Clin Pharmacol Drug Dev; 2022 Sep; 11(9):1092-1098. PubMed ID: 35403832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.
    Bogler Y; Stern A; Su Y; Lee YJ; Seo SK; Shaffer B; Perales MA; Papanicolaou GA; Neofytos D
    Med Mycol; 2021 Oct; 59(10):970-979. PubMed ID: 34036319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients.
    Wu X; Clancy CJ; Rivosecchi RM; Zhao W; Shields RK; Marini RV; Venkataramanan R; Nguyen MH
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30275091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isavuconazole Is as Effective as and Better Tolerated Than Voriconazole for Antifungal Prophylaxis in Lung Transplant Recipients.
    Samanta P; Clancy CJ; Marini RV; Rivosecchi RM; McCreary EK; Shields RK; Falcione BA; Viehman A; Sacha L; Kwak EJ; Silveira FP; Sanchez PG; Morrell M; Clarke L; Nguyen MH
    Clin Infect Dis; 2021 Aug; 73(3):416-426. PubMed ID: 32463873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.
    Stern A; Su Y; Lee YJ; Seo S; Shaffer B; Tamari R; Gyurkocza B; Barker J; Bogler Y; Giralt S; Perales MA; Papanicolaou GA
    Biol Blood Marrow Transplant; 2020 Jun; 26(6):1195-1202. PubMed ID: 32088367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.
    Kovanda LL; Marty FM; Maertens J; Desai AV; Lademacher C; Engelhardt M; Lu Q; Hope WW
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study).
    Monforte A; Los-Arcos I; Martín-Gómez MT; Campany-Herrero D; Sacanell J; Berastegui C; Márquez-Algaba E; Sempere A; Nuvials X; Deu M; Castells L; Moreso F; Bravo C; Gavaldà J; Len O
    Microbiol Spectr; 2022 Feb; 10(1):e0178421. PubMed ID: 35171022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic investigations of isavuconazole in paediatric cancer patients show reduced exposure of isavuconazole after opening capsules for administration via a nasogastric tube.
    Bury D; Wolfs TFW; Ter Heine R; Muilwijk EW; van der Elst KCM; Tissing WJE; Brüggemann RJM
    J Antimicrob Chemother; 2023 Dec; 78(12):2886-2889. PubMed ID: 37864491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isavuconazole therapeutic drug monitoring in critically ill ICU patients: A monocentric retrospective analysis.
    Höhl R; Bertram R; Kinzig M; Haarmeyer GS; Baumgärtel M; Geise A; Muschner D; Prosch D; Reger M; Naumann HT; Ficker JH; Kubitz J; Steinmann J; Sörgel F
    Mycoses; 2022 Jul; 65(7):747-752. PubMed ID: 35535740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.
    Murrell D; Bossaer JB; Carico R; Harirforoosh S; Cluck D
    Int J Pharm Pract; 2017 Feb; 25(1):18-30. PubMed ID: 27569742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH.
    Schmitt-Hoffmann A; Desai A; Kowalski D; Pearlman H; Yamazaki T; Townsend R
    Int J Clin Pharmacol Ther; 2016 Aug; 54(8):572-80. PubMed ID: 27345284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.
    Marty FM; Ostrosky-Zeichner L; Cornely OA; Mullane KM; Perfect JR; Thompson GR; Alangaden GJ; Brown JM; Fredricks DN; Heinz WJ; Herbrecht R; Klimko N; Klyasova G; Maertens JA; Melinkeri SR; Oren I; Pappas PG; Ráčil Z; Rahav G; Santos R; Schwartz S; Vehreschild JJ; Young JH; Chetchotisakd P; Jaruratanasirikul S; Kanj SS; Engelhardt M; Kaufhold A; Ito M; Lee M; Sasse C; Maher RM; Zeiher B; Vehreschild MJGT;
    Lancet Infect Dis; 2016 Jul; 16(7):828-837. PubMed ID: 26969258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isavuconazole for the Treatment of Invasive Mold Disease in Solid Organ Transplant Recipients: A Multicenter Study on Efficacy and Safety in Real-life Clinical Practice.
    Fernández-Ruiz M; Bodro M; Gutiérrez Martín I; Rodriguez-Álvarez R; Ruiz-Ruigómez M; Sabé N; López-Viñau T; Valerio M; Illaro A; Fortún J; Salto-Alejandre S; Cordero E; Fariñas MDC; Muñoz P; Vidal E; Carratalà J; Goikoetxea J; Ramos-Martínez A; Moreno A; Aguado JM;
    Transplantation; 2023 Mar; 107(3):762-773. PubMed ID: 36367924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of isavuconazonium sulfate and its active metabolite isavuconazole in healthy dogs.
    McQuinn E; Mochel JP; Borts D; Hanzlicek AS; Allenspach K; Palerme JS
    PLoS One; 2024; 19(7):e0305766. PubMed ID: 39012876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases.
    Kaindl T; Andes D; Engelhardt M; Saulay M; Larger P; Groll AH
    J Antimicrob Chemother; 2019 Mar; 74(3):761-767. PubMed ID: 30476108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.
    Miceli MH; Kauffman CA
    Clin Infect Dis; 2015 Nov; 61(10):1558-65. PubMed ID: 26179012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.